Jpmorgan Chase & CO Immunic, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Immunic, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,265 shares of IMUX stock, worth $834. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,265
Previous 6,216
79.65%
Holding current value
$834
Previous $6,000
83.33%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IMUX
# of Institutions
75Shares Held
40.2MCall Options Held
1.14MPut Options Held
130K-
Bvf Inc San Francisco, CA8.9MShares$5.88 Million0.43% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$4.81 Million0.66% of portfolio
-
Avidity Partners Management LP Dallas, TX4.45MShares$2.94 Million1.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.93MShares$2.59 Million0.0% of portfolio
-
Gratus Capital LLC2.11MShares$1.39 Million0.1% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $20.2M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...